Preview Mode Links will not work in preview mode


Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show is a window into the latest innovations in digital health and the changing dynamic between doctors and patients.

Topics on the show include

  • the emergence of precision medicine and breakthroughs in genomics
  • advances in biopharmaceuticals
  • age-related diseases and aging in place
  • using big data from wearables and sensors
  • transparency in the medical marketplace
  • challenges for connected health entrepreneurs

The audience includes researchers, medical professionals, patient advocates, entrepreneurs, patients, caregivers, solution providers, students, journalists, and investors.

Oct 25, 2021

Dr. Daniel Schneeberger is the CEO of Anebulo Pharmaceuticals and is determined to find an antidote to acute cannabinoid intoxication, a growing problem for people of all ages as well as emergency rooms around the country.

Daniel says, "THC acts mostly in the brain, it crosses the blood-brain barrier and binds to the CB1 receptor, and it activates that CB1 receptor. Our drug also goes to the brain and binds to the same receptor, much more tightly, up to 100x more tightly, and blocks it so that THC has no chance to act on that receptor anymore. One of the most important properties of our drug, too, is rapid absorption with oral dosing. So we feel very good about the drug candidate."

"These drugs, CB1 antagonists, were originally developed for weight loss in the treatment of diabetes back around 2007, 2008. They were never approved by the FDA because with chronic dosing, there was an increased frequency of depression, it was 9%, it was 5% with placebo. Back then, the FDA was very concerned that chronic dosing in such a large patient population might potentially be unsafe. For our drug, it's a one-time dose, and those mood effects only showed up with chronic dosing."

@AnebuloP #CannabisIntoxication #AcuteCannabisIntoxication #Cannabinoids #SyntheticCannabinoids #SubstanceAbuseDisorders

Anebulo Pharmaceuticals

Listen to the podcast here